

Research Article

Cardiology: Open Access

Plasma Renin Activity after Diuretic Treatment in Patients with Stable Heart Failure: With Special Reference to its Association with Electrolyte Chloride

Hajime Kataoka

Internal Medicine, Nishida Hospital, Oita, Japan

***Corresponding author**

Hajime Kataoka, Internal Medicine, Nishida Hospital, 2-266 Tsuruoka-Nishi-machi, Saiki-city, Oita 876-0047, Japan.

Submitted: 23 Apr 2021; Accepted: 29 Apr 2021; Published: 08 May 2021

Citation: Hajime Kataoka (2021) Plasma Renin Activity after Diuretic Treatment in Patients with Stable Heart Failure: With Special Reference to its Association with Electrolyte Chloride. *Cardio Open*, 6(2): 132-142.

Abstract

A recent study reported an intimate association between urinary chloride (Cl) and plasma renin activity (PRA) in acute heart failure (HF) status, reflecting normal functioning of the 'tubulo-glomerular feedback' mechanism. Whether the 'tubulo-glomerular feedback' mechanism functions normally in stable HF status, however, is unclear. This study examined whether the 'tubulo-glomerular feedback' mechanism functions normally under resolution of worsening HF after decongestive therapy. Data from 26 patients with acute HF and its recovery after decongestive therapy were analyzed. Clinical tests included measurement of peripheral blood tests, serum and spot urinary electrolytes, plasma neurohormones, and fractional urinary excretions of electrolytes. In a total of 26 patients, PRA increased after acute HF treatment (from 1.64 ± 2.0 to 5.48 ± 6.1 ng/mL/h, $p=0.002$). Changes in the serum logPRA and urinary Cl concentration from worsening to its recovery tended to be inversely correlated ($R^2=0.12$, $p=0.085$) and logPRA and the serum Cl concentration at recovery were inversely correlated ($R^2=0.23$, $p=0.01$). When divided into 2 groups ($n=13$ in each) according to the median PRA, the group with greater PRA changes showed a larger decrease in the urinary Cl concentration (from 110 ± 44 to 72.8 ± 38 , $p=0.03$). The group with higher PRA at recovery showed a lower serum Cl concentration than the group with lower PRA at recovery (102 ± 6.5 vs 107 ± 4.2 mEq/L, $p=0.04$). In conclusion, the association between PRA and the serum/urinary Cl concentration is blunted in stable HF under-decongestive therapy, possibly due to the physiologic status under full cardiovascular medication compared with that in acute HF status.

Keywords: Heart Failure, Chloride, Urinary Chloride Concentration, Tubulo-Glomerular Feedback, Plasma Renin Activity

Introduction

In the kidney, renal salt sensing and renin secretion are dependent on macula densa chloride (Cl) transport at the juxta-glomerular apparatus, which is central to the 'tubulo-glomerular feedback' mechanism [1-4]. A recent clinical study reported an inverse correlation between the urinary Cl concentration and plasma renin activity (PRA) in acute heart failure (HF) status, reflecting normal 'tubulo-glomerular feedback' function in the human body [5]. The relation of electrolyte Cl to this mechanism in clinically stable HF, however, remains unclear.

Thus, the present study evaluated the performance of the 'tubulo-glomerular feedback' mechanism in stable HF by analyzing the association between PRA and the serum/urinary Cl concentration in patients with stable chronic HF patients following decongestive therapy. Additionally, this study sought to explore the clinical evidence supporting the 'chloride theory' in HF patients receiving

decongestive therapy [6-8].

Methods
Study Design

This study was a single-center observational study that enrolled consecutive 31 patients with acute HF at Nishida Hospital (Saiki-city, Oita, Japan) undergoing neurohormonal study between March 2017 and April 2018. Diagnosis of worsening of HF was established by standard clinical criteria of presentation, echocardiography, and serum b-type natriuretic peptide (BNP) [9]. Additional routine tests included thoracic ultrasound to evaluate the presence of pleural effusion [10,11] and monitoring the changes in body weight during follow-up (HBF-352-W, Omron Healthcare Co., Kyoto, Japan) [12]. Worsening HF was treated by conventional therapy with a combination of loop diuretics, aldosterone blockade, thiazide diuretics, oral vasopressin antagonist, acetazolamide, and/or inotropic drugs by oral and/or intravenous routes in the hos-

pital or outpatient clinic. Based on the follow-up examination, the response of worsening HF to treatment and return of the clinical presentation to stable HF status were determined. Acute HF patients with cardiogenic shock, clinical diagnosis of acute coronary syndrome, or known advanced renal disease (serum creatinine level >3.0 mg/dL) were excluded from the present study.

Data Collection and Analytic Methods

Physical examination, blood tests of peripheral venous blood, and a spot urine test for electrolytes and creatinine were performed twice, i.e., at acute HF condition immediately before initiation of treatment, and at stable HF condition after well-done decongestive therapy. The blood and urine samples were obtained after patients rested in a supine or semi-supine position for 20-min. Peripheral blood tests, analyzed by standard techniques, included hemoglobin, hematocrit, serum electrolytes (sodium, potassium, and Cl), blood urea nitrogen, and creatinine. The spot urine test included measurement of electrolytes and creatinine concentrations, and osmolality. Plasma BNP was measured by chemiluminescent immunoassay. Plasma adrenaline and noradrenaline were measured by high performance liquid chromatography. Plasma renin activity was measured by enzyme immunoassay. Plasma aldosterone and arginine vasopressin (AVP) levels were measured by radioimmunoassay. The Strauss formula is used to estimate percentage (%) change in plasma volume [13,14]: % change in plasma volume = $\frac{[(Hb1/Hb2) \times (100-Hct2)/(100-Hct1) - 1] \times 100}{1}$, where 1=baseline and 2=end values, Hb=hemoglobin, and Hct=hematocrit. Fractional excretions of electrolytes were calculated as: fraction-

al excretion of $X = \frac{(X_{urine}/X_{serum}) \times (Cr_{serum}/Cr_{urine}) \times 100}{1}$ [15]. Urinary osmotic pressure was measured by the freezing point depression method using an OM-6060 type automatic osmotic pressure measuring device (Arkray Inc., Kyoto, Japan).

Statistical Analysis

All data are expressed as mean±SD for continuous data and percentage for categorical data. Paired and unpaired t tests for continuous data were used for two-group comparisons. Pearson's correlation was performed to evaluate the linear association between logarithmically transformed PRA and other variables. A *p* value of <0.05 was considered statistically significant.

Results

Of the 31 acute HF patients, 5 were excluded from the present study because of lacked clinical data for analysis of the present study due to cardiac death during follow-up in 3 patients and insufficient data in 2. The remaining 26 patients (50% men; 81.2±12 years), including de novo acute HF patients (n=9), were enrolled in the present analysis. Clinical characteristics and maintenance medical use of study patients at acute HF presentation is shown in Table 1. All study patients presented with two to four HF signs on the basis of physical examination and searching for pleural effusion by thoracic ultrasound. Plasma BNP levels were elevated definitely (≥ 500 pg/mL) in 18 patients, moderately (500 pg/mL > to 200 pg/mL) in 6, and mildly (200 pg/mL > to 100 pg/mL) in 2. Treatment for acute HF was undertaken in hospital in 21 patients, and outpatient clinic in 5 patients.

Table 1: Clinical characteristics of the study patients at presentation of worsening heart failure

Characteristics		Total N = 26
Age (years)		
	Mean ± SD	81.2±12
	Range	53-97
Male		13 (50)
Primary cause of HF		
	Hypertension	18 (69)
	Valvular	4 (15)
	Ischemic/Cardiomyopathy	3 (12)
	Arrhythmia	1 (4)
Left ventricular EF (%)		
	Mean ± SD	46.8±18
Left ventricular EF > 50%		14 (54)
Atrial fibrillation		13 (50)
NYHA-FC at acute HF presentation		
	III	5 (19)
	IV	21 (81)
HF-related physical findings at acute HF presentation		
	Bilateral leg edema around or above the ankle	22 (85)
	Bilateral pulmonary rales beyond the basal lung	20 (77)
	Pleural effusion on thoracic ultrasound	23 (88)

	Third heart sound (S3)	5 (19)
	Number of HF sings (Mean±SD; range)	2.69±0.62; 2-4
B-type natriuretic peptide (pg/mL) at acute HF presentation		
	2000≥	1 (4)
	2000 – 1000	5 (19)
	1000 – 500	12 (46)
	500 – 200	6 (23)
	200 – 100	2 (8)
Baseline medication use at acute HF presentation		
	De novo HF patients without diuretic treatment	9 (35)
	Diuretics	
	Loop diuretics	11 (42)
	Thiazide diuretics	15 (14)
	MRA	11 (42)
	Tolvaptan	5 (19)
	Acetazolamide	8 (31)
	ACE inhibitors/ARB	10 (34)
	Beta-blockers	7 (27)
	Calcium antagonists	8 (31)

Data presented as number (%) of patients otherwise specified. ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blocker, EF: ejection fraction, MRA: mineralocorticoid receptor antagonist, NYHA-FC: New York Heart Association functional class, HF: heart failure.

After decongestive treatment for 25.2±17 (range 7–78) days, all the study patients responded well to the treatment, resulting in disappearance of ≥2 HF-related signs in each, and minimal residual HF-related signs remained to be observed in only 5 patients (persistent basal rales in 3 and minimal pleural effusion in 2). Table 2 shows changes in the physical and blood laboratory results under diuretic treatment. Systolic and diastolic pressures, heart rate, and plasma logBNP levels decreased. Plasma volume estimated by the Strauss method and serum electrolyte concentrations did

not change, whereas the serum blood urea nitrogen and creatinine concentrations increased. Urinary Cl and potassium concentrations decreased following decongestive therapy. Plasma adrenaline and noradrenaline concentrations decreased, but PRA and aldosterone concentrations increased. Individual logPRA values were widely distributed from relatively low to high in worsening HF (Figure 1A) and its recovery following decongestive therapy (Figure 1B). The histogram of logPRA shifted up in patients after receiving decongestive treatment for worsening HF.

Figure 1. Distribution of log plasma renin activity (logPRA) in the 26 study patients under




Table 2: Changes in physical and laboratory tests after decongestive treatment in 26 heart failure patients

		Normal range	Before	After	After vs. Before (increase/unchanged/decrease)	p value
Physical examination						
	Blood pressure (mmHg)					
	Systolic pressure		135 ± 34	119 ± 17	8/ 0/ 18	0.0024*
	Diastolic pressure		76.4 ± 21	66.1 ± 12	8/ 0/ 18	0.013*
	Heart rate (bpm)		86 ± 21	71.7 ± 14	6/ 1/ 19	0.002*
	LogBNP (pg/mL)		2.81 ± 0.34	2.25 ± 0.31	0/ 0/ 26	<0.0001*
Peripheral blood test						
	Hemoglobin (g/dL)	11.6–14.8	11.7 ± 2.1	12.0 ± 2.5	15/ 1/ 10	0.28
	Hematocrit (%)	35.1–44.4	35.4 ± 6.0	35.9 ± 6.9	13/ 0/ 13	0.48
	%Changes in plasma volume		—	-0.2 ± 6.3	13/ 0/ 13	—
Serum electrolytes						
	Sodium (mEq/L)	138–145	139 ± 5.1	139 ± 4.7	12/ 5/ 9	0.82
	Potassium (mEq/L)	3.6–4.8	4.27 ± 0.68	4.12 ± 0.51	8/ 3/ 15	0.28
	Chloride (mEq/L)	101–108	104 ± 5.7	104 ± 5.8	11/ 1/ 14	0.71
	Blood urea nitrogen (mg/dL)	8.0–20.0	26.5 ± 11	38.7 ± 19	22/ 1/ 3	0.0008*
	Serum creatinine (mg/dL)	0.46–0.79	1.26 ± 0.56	1.43 ± 0.60	20/ 1/ 5	0.004*
	Uric acid (mg/dL)	3.7-7	6.38 ± 2.41	7.43 ± 2.12	20/ 0/ 6	0.023*
Spot urinary examination						
	Concentration of urinary electrolytes					
	Sodium (mEq/L)		91.6 ± 45	78.7 ± 33	9/ 0/ 17	0.14
	Potassium (mEq/L)		29.7 ± 15	24.2 ± 9.6	8/ 0/ 18	0.038*
	Chloride (mEq/L)		93.0 ± 48	68.8 ± 34	8/ 1/ 17	0.035*
	% excretion of urinary electrolytes					
	Sodium (%)		2.18 ± 2.1	2.09 ± 2.3	13/ 0/ 13	0.88
	Potassium (%)		16.0 ± 9.8	13.5 ± 7.6	8/ 0/ 18	0.25
	Chloride (%)		2.9 ± 2.9	2.09 ± 2.3	8/ 0/ 18	0.28
	Osmolality (mOsm/kg H ₂ O)		473 ± 184	452 ± 155	13/ 0/ 13	0.53
Neurohormonal test						
	Adrenaline (pg/mL)	< 0.1	0.085 ± 0.08	0.048 ± 0.05	5/ 1/ 20	0.005*
	Noradrenaline (pg/mL)	0.1–0.5	0.96 ± 0.6	0.52 ± 0.3	5/ 0/ 21	0.001*
	Renin activity (ng/mL/h)	0.2–2.3	1.64 ± 2.0	5.48 ± 6.1	22/ 0/ 4	0.002*
	Aldosterone (pg/mL)	36–240	117 ± 90	209 ± 257	19/ 0/ 7	0.039*
	AVP (pg/mL)	< 2.8	3.54 ± 3.4	3.97 ± 6.1	13/ 1/ 12	0.59

*Statistically significant difference between before and after treatment ($p < 0.05$, paired t test). AVP: arginine vasopressin, BNP: b-type natriuretic peptide.

As shown in Table 3, among a total of 26 study patients, changes in the serum logPRA and urinary Cl concentrations from worsening HF to its recovery tended to be inversely correlated ($R^2=0.12$,


$p=0.085$; Figure 2A), and logPRA and serum Cl concentrations at recovery were inversely correlated ($R^2=0.23$, $p=0.01$; Figure 2B).

Table 3: Pearson's correlation of delt logPRA from worsening HF to its recovery or logPRA at recovery to multiple variables in stable HF status following decongestive therapy (Total N = 26)


Variable	Change in LogPRA (ng/mL/h) from worsening HF to its recovery		LogPRA (ng/mL/h) at recovery from worsening HF	
	R ²	p value	R ²	p value
LogBNP (pg/mL)	0.05	0.26	0.09	0.64
Systolic BP (mmHg)	0.0002	0.95	0.012	0.59
Diastolic BP (mmHg)	0.1	0.11	0.18	0.029*
Heart rate (beats/min)	0.024	0.44	0.09	0.13
% change in plasma volume (%)	0.018	0.52	0.014	0.56
Serum electrolytes				
Sodium (mEq/L)	0.08	0.17	0.08	0.15
Potassium (mEq/L)	0.02	0.47	0.1	0.12
Chloride (mEq/L)	0.11	0.096	0.23	0.01*
BUN (mg/dL)	0.23	0.014*	0.03	0.41
Creatinine (mg/dL)	0.045	0.3	0.09	0.14
Urinary concentration				
Sodium (mEq/L)	0.18	0.03*	0.04	0.31
Potassium (mEq/L)	0.02	0.49	0.12	0.09
Chloride (mEq/L)	0.12	0.085	0.01	0.6
Osmolality (mOsm/kg H ₂ O)	0.02	0.48	0.04	0.36
Adrenaline (pg/mL)	0.08	0.17	0.19	0.027*
Noradrenaline (pg/mL)	0.005	0.74	0.06	0.22
Aldosterone (pg/mL)	0.24	0.01*	0.24	0.01*
AVP (pg/mL)	0.08	0.16	0.06	0.22

AVP: arginine vasopressin, BNP: b-type natriuretic peptide, BP: blood pressure, BUN: blood urea nitrogen, HF: heart failure, PRA: plasma renin activity.

Figure 2. Correlations between



(A) log plasma renin activity (logPRA) and urinary chloride (Cl) concentration



(B) logPRA and the serum Cl concentration.

Table 4 shows low vs high groups of the 2 different categories of
 (A) changes in PRA from worsening HF to its recovery and
 (B) PRA at recovery from worsening HF stratified by splitting the same study population according to each median value.

Table 4: Comparison of blood chemistries and neurohormones between low and high groups stratified by (A) changes in PRA from worsening HF to its recovery or (B) PRA at recovery from worsening HF in 26 HF patients

		(A) Change in PRA from worsening HF to its recovery		<i>p</i> value	(B) PRA at recovery from worsening HF		<i>p</i> value
		Low (n=13)	High (n=13)		Low (n=13)	High (n=13)	
Renin activity (ng/mL/h)							
	Worsening	2.35 ± 2.4	0.92 ± 1.2	0.07	–	–	
	Recovery	3.49 ± 3.9	7.45 ± 7.3	0.1	1.55 ± 0.94	9.40 ± 6.6	0.0003*
	Δworse to recovery	1.13 ± 1.9	6.55 ± 6.8	0.01*			
	<i>p</i> value	0.05	0.005*				
Physical examination							
Systolic pressure (mmHg)							
	Worsening	141 ± 34	130 ± 35	0.46	–	–	
	Recovery	120 ± 19	118 ± 16	0.87	121 ± 19	117 ± 16	0.49
	Δworse to recovery	-21 ± 25	-11.9 ± 25	0.36			
	<i>p</i> value	0.01*	0.11				
Diastolic pressure (mmHg)							
	Worsening	81.3 ± 26	71.4 ± 14	0.23	–	–	
	Recovery	65.2 ± ±13	67.0 ± 11	0.71	62.5 ± 13	69.7 ±10	0.13
	Δworse to recovery	-16.1 ± 24	-4.4 ± 11	0.13			
	<i>p</i> value	0.03*	0.19				
Heart rate (bpm)							
	Worsening	85.2 ± 17	86.8 ± 25	0.89	–	–	
	Recovery	72.2 ± 13	71.2 ± 15	0.84	67.9 ± 9.7	75.5 ± 16	0.16
	Δworse to recovery	-13.0 ± 17	-15.6 ± 25	0.76			
	<i>p</i> value	0.02*	0.04*				
LogBNP (pg/mL)							
	Worsening	2.85 ± 0.35	2.78 ± 0.34	0.59	–	–	
	Recovery	2.18 ± 0.26	2.32 ± 0.35	0.24	2.19 ± 0.31	2.31 ± 0.32	0.37
	Δworse to recovery	-0.67 ± 0.35	-0.45 ± 0.26	0.08			
	<i>p</i> value	<0.0001*	<0.0001*				
Peripheral blood test							
%Changes in plasma volume							
	Mean±SD	-0.13 ± 7.3	-0.26 ± 5.4	0.96	-0.09 ± 7.2	-0.3 ± 5.5	0.94
	Range	-9.9 ~ 16.3	-7.4 ~ 9.6				

Sodium (mEq/L)								
		Worsening	139 ± 4.8	139 ± 5.6	0.79	–	–	
		Recovery	140 ± 3.2	138 ± 5.8	0.36	139±4.0	139±5.4	0.68
		Δworse to recovery	1.31 ± 3.1	-0.9 ± 5.1	0.19			
		<i>p</i> value	0.16	0.53				
Potassium (mEq/L)								
		Worsening	4.42 ± 0.68	4.13 ± 0.68	0.3	–	–	
		Recovery	4.24 ± 0.62	3.99 ± 0.36	0.23	4.36 ± 0.50	3.87 ± 0.4	0.01*
		Δworse to recovery	-0.20 ± 0.71	-0.10 ± 0.78	0.9			
		<i>p</i> value	0.39	0.53				
Chloride (mEq/L)								
		Worsening	105 ± 6.0	103 ± 5.6	0.32	–	–	
		Recovery	107 ± 3.9	101 ± 6.2	0.01*	107 ± 4.2	102 ± 6.5	0.04*
		Δworse to recovery	2.23 ± 5.8	-1.15 ± 8.3	0.24			
		<i>p</i> value	0.19	0.62				
Blood urea nitrogen (mg/dL)								
		Worsening	32.8 ± 9.9	20.2 ± 8.9	0.02*	–	–	
		Recovery	38.9 ± 15.5	38.6 ± 23.4	0.97	35.5 ± 13	42.0 ± 24	0.4
		Δworse to recovery	6.13 ± 10.5	18.3 ± 19.1	0.05			
		<i>p</i> value	0.06	0.005*				
Serum creatinine (mg/dL)								
		Worsening	1.52 ± 0.68	1.0 ± 0.25	0.02*	–	–	
		Recovery	1.62 ± 0.71	1.23 ± 0.40	0.1	1.56 ± 0.65	1.30 ± 0.54	0.28
		Δworse to recovery	0.10 ± 0.3	0.24 ± 0.23	0.22			
		<i>p</i> value	0.26	0.003*				
Spot urinary examination								
Sodium (mEq/L)								
		Worsening	74.5 ± 43	109 ± 42	0.79	–	–	
		Recovery	75.2 ± 28	82.2 ± 39	0.37	86.6 ± 30	70.7 ± 35	0.23
		Δworse to recovery	0.62 ± 41	-26.0 ± 42	0.19			
		<i>P</i> value	0.96	0.04*				
Potassium (mEq/L)								
		Worsening	31.2 ± 15	28.3 ± 15	0.3	–	–	
		Recovery	22.6 ± 8.9	25.8 ± 10	0.23	21.3 ± 6.9	27.1 ± 11	0.13
		Δworse to recovery	-8.54 ± 13	-2.54 ± 13	0.9			
		<i>p</i> value	0.03*	0.49				
Chloride (mEq/L)								
		Worsening	75.5 ± 48	110 ± 44	0.07	–	–	

	Recovery	64.8 ± 31	72.8 ± 38	0.57	73.8 ± 26	63.9 ± 42	0.47
	Δworse to recovery	-11.0 ± 52	-38.0 ± 57	0.22			
	<i>p</i> value	0.47	0.03*				
Neurohormonal test							
Adrenaline (pg/mL)							
	Worsening	0.07 ± 0.04	0.10 ± 0.10	0.22	–	–	
	Recovery	0.046 ± 0.05	0.05 ± 0.04	0.85	0.028 ± 0.02	0.07 ± 0.006	0.03*
	Δworse to recovery	-0.02 ± 0.05	-0.05 ± 0.07	0.15			
	<i>p</i> value	0.13	0.01*				
Noradrenaline (pg/mL)							
	Worsening	0.92 ± 0.63	0.99 ± 0.65	0.75	–	–	
	Recovery	0.53 ± 0.41	0.51 ± 0.23	0.87	0.44 ± 0.29	0.61 ± 0.35	0.19
	Δworse to recovery	-0.38 ± 0.55	-0.48 ± 0.67	0.67			
	<i>p</i> value	0.03*	0.02*				
Aldosterone (pg/mL)							
	Worsening	134 ± 94	97.9 ± 86	0.29	–	–	
	Recovery	160 ± 116	258 ± 346	0.34	131 ± 102	287 ± 338	0.12
	Δworse to recovery	23.9 ± 92	160 ± 279	0.11			
	<i>p</i> value	0.37	0.06				
Cardiovascular medication							
	Loop diuretics	12	11	1	11	12	1
	Thiazide diuretics	2	2	1	1	3	0.59
	MRA	9	13	0.1	10	12	0.59
	Tolvaptan	3	3	1	1	5	0.16
	Acetazolamide	9	8	1	9	8	1
	ACE inhibitors/ARB	6	4	1	7	3	0.23
	Beta-blockers	6	6	0.69	3	9	0.047*

*Statistically significant difference between before and after treatment ($p < 0.05$, paired t test). ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blocker, BNP: b-type natriuretic peptide, HF: heart failure, MRA: mineralocorticoid receptor antagonist, PRA: plasma renin activity.

Usage of cardiovascular medication was not different between the low and high groups in each of the 2 different categories, except for the more frequent use of beta-blockers in the high PRA group compared with the low PRA group in category (B) at recovery from worsening HF.

When divided into 2 groups according to the changes in PRA from worsening HF to its recovery (A: Table 4), both groups showed similar changes from worsening to recovery in physical examination, logBNP, plasma volume, serum sodium, potassium and Cl electrolytes, and neurohormonal levels. The high-change group showed significantly increased serum concentrations of blood urea nitrogen and creatinine, and significantly decreased urinary concentrations of sodium (from 109±42 to 82.2±39 mEq/L, $p=0.04$)

and Cl (from 110±44 to 72.8±38 mEq/L, $p=0.03$) after decongestive therapy.

When divided into 2 groups according to the median value of PRA at recovery (B: Table 4), the high-PRA group presented with lower serum potassium (3.87±0.4 vs 4.36±0.50 mEq/L, $p=0.01$) and Cl (102±6.5 vs 107±4.2, mEq/L, $p=0.04$) concentrations compared with the low-PRA group.

Discussion

The present study revealed that PRA was enhanced following decongestive therapy, but individual activity widely distributed from low to high levels. The association between PRA and the serum/urinary Cl concentration was blunted in stable HF after recovery

from worsening HF, possibly due to the physiologic status under full cardiovascular medication compared with inadequate cardiovascular medication in acutely worsening HF [5].

Plasma Renin Activity after Decongestive Treatment for Acute HF

The present study confirmed that PRA was increased after decongestive treatment, consistent with previous studies [8,16-20]. The main mechanism for the renin activity under treatment with conventional diuretics is reported to be diuretic-induced plasma volume contraction [21,22], but other potential mechanisms of enhanced renin activity due to a decreased supply of Cl in the macula densa cells and consequent enhancement of renin secretion by 'tubulo-glomerular feedback' are as follows: 1) blockade of the entrance of Cl into the macula densa cells by loop diuretics [23], and/or 2) decreased Cl supply to macula densa cells due to hypochloremia, as predicted by the 'chloride theory' [6]. No apparent association of PRA with diuretic-induced plasma volume changes as evaluated by the Strauss method was detected in the present study.

As for electrolyte Cl, our recent study examining pre-treatment acute HF patients provided clinical evidence for normal function of urinary Cl involved in the 'tubulo-glomerular feedback' mechanism by disclosing an inverse association between the urinary Cl concentration and PRA [5]. In the present study, PRA was weakly associated with the serum Cl concentration ($R^2=0.23$, $p=0.01$; Figure 2B). PRA tended to be associated with the urinary Cl concentration ($R^2=0.12$, $p=0.085$; Figure 2A), but the trend did not reach statistical significance. The present study demonstrated that the 'tubulo-glomerular feedback' mechanism is blunted in stable HF, but the clinical significance of this finding is unclear, as discussed below.

Plasma Renin Activity and Cl in Stable HF with Respect to the 'Tubulo-Glomerular Feedback' Mechanism

As mentioned above, most clinical studies [8,16-20] report enhanced PRA following decongestive therapy for acute HF, but clinical investigations of the association of PRA with the electrolyte Cl, by which the electrolyte renin-angiotensin-aldosterone mechanism is basically regulated, are scarce. Similar to the present study, Hanberg et al, demonstrated an independent association between PRA and the serum Cl concentration [24]. The study by Hanberg et al, included 162 chronic HF patients taking loop diuretics, of whom 111 had hypochloremia (serum chloride ≤ 96 mmol/L) and 51 had normochloremia (serum chloride >96 mmol/L) [24]. They observed that the total renin level was higher in patients with hypochloremia compared to those without hypochloremia. Plasma renin levels were negatively and independently correlated with serum Cl concentrations whereas the correlation with the serum sodium concentration was less pronounced.

Our recent study examining acute HF patients provided definitive proof of normal 'tubulo-glomerular feedback' function in the human body by demonstrating a significant association between the spot urinary Cl concentration and PRA [5]. Unfortunately, the present study could not find such an intimate association between the spot urinary Cl concentration and PRA, but instead demonstrated a significant and inverse relationship between PRA and se-

rum Cl concentrations in stable HF (Figure 2), similar to the report by Hanberg et al, [24].

The inability to detect a significant association between the urinary Cl concentration and PRA in stable HF might be due to:

- 1) the lack of statistical power to detect an association because of the small sample size, 2) a blunted response of the macula densa to the urinary Cl concentration caused by adaptation of the 'tubulo-glomerular feedback' mechanism in chronic HF status [3], 3) the existence of many confounding factors influencing the electrolyte Kinetics, [25,26], and 4) the effects of treatment with neurohormonal blockers and diuretics for maintaining a stable HF condition [19,20]. With regard to the latter possibility, Pearson's correlation between the serum and urinary Cl concentrations was nearly equal between data obtained in acute HF status ($n=29$, $R^2=0.13$, $p=0.06$) and data obtained in stable HF status ($n=26$, $R^2=0.13$, $p=0.05$).

Despite a similar relation between the serum and urinary Cl concentrations, the lack of a significant association between the urinary Cl concentration and PRA under stable HF status might be related to a presumed modification of urinary contents induced by a strict medication regimen, with the progression of glomerularly filtered plasma running through the renal tubules into the bladder, compared with insufficient treatment in acute HF status [27,28]. Future studies are required to resolve this issue.

Clinical Proof of the 'Chloride Theory' for HF Pathophysiology

The 'chloride theory' for HF pathophysiology states that changes in the serum Cl concentration are the primary determinant of changes in the plasma volume and renin-angiotensin-aldosterone system [6]. Under decongestive therapy for worsening HF, this theory predicts that PRA would be enhanced under lowering of the serum Cl concentration by Cl-depleting diuretic therapy, such as the use of loop/thiazide diuretics. In contrast, renin activity would likely be depressed or suppressed when the serum Cl concentration is enhanced by treatment with Cl-regaining diuretics or Cl supplementary treatment [6,8,29]. Observations of the present study support the 'chloride theory' for HF pathophysiology [6-8] by disclosing interactions between the serum Cl concentration and neurohormonal activities during resolution of acute HF, i.e., stable HF patients with low PRA had high serum Cl concentrations, and conversely, those with high PRA had low serum Cl concentrations (Table 4). Thus, the 'chloride theory' for HF pathophysiology [6-8] could provide a primary care management system for diuretic treatment of HF patients, with attention to the serum Cl concentration and changes central to this system [29].

Study Limitations

This study was a single-center observational study performed with a relatively small number of patients, and should thus be considered as hypothesis-generating. In addition, the present results were derived from a population of mild-to-moderate HF patients. Enhanced PRA is frequently observed in patients with advanced HF and hypovolemia, but not in those with mild to moderate HF [19,21,22,30]. Furthermore, body fluid retention induced by a high sodium diet or diuretic withdrawal in patients with mild to moderate HF depressed the PRA [31-33]. As such, PRA may widely fluctuate in stable HF status. Therefore, extrapolation of the results

of this study cannot be generalized to patients with more advanced HF. Further studies including a larger number of HF patients are needed to better assess the clinical implications of PRA measurements in HF pathophysiology.

Conclusions

Except for several clinical studies of HF pathophysiology, PRA has not been evaluated in association with the kinetics of Cl, although this electrolyte is key for regulating renin release in the macula densa [5,24]. The present findings suggest that ‘tubulo-glomerular feedback’ functions normally in stable HF by showing a trend toward a significant and inverse association between PRA and the urinary Cl concentration, but its function is blunted in stable HF under-decongestive therapy, possibly due to the physiologic status under full cardiovascular medication compared with that in acute HF status.

References

1. Lorenz JN, Weihprecht H, Schnermann J, Skøtt O, Briggs JP (1991) Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. *Am J Physiol* 260: F486-F493.
2. He X-R, Greenberg SG, Briggs JP, Schnermann J (1995) Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion. *Hypertension* 26: 137-142.
3. Schnermann J (1998) Juxtaglomerular cell complex in the regulation of renal salt excretion. *Am J Physiol* 274: R263-R279.
4. Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, et al. (2014) The kidney in congestive heart failure: ‘Are natriuresis, sodium, and diuretics really the good, the bad and the ugly?’ *Eur J Heart Fail* 16: 133-142.
5. Kataoka H (2021) Clinical significance of spot urinary chloride concentration measurements in patients with acute heart failure: Investigation on the basis of the ‘tubulo-glomerular feedback’ mechanism. *Cardio Open* 6: 123-131.
6. Kataoka H (2017) The “chloride theory”, a unifying hypothesis for renal handling and body fluid distribution in heart failure pathophysiology. *Med Hypotheses* 104: 170-173.
7. Kataoka H (2019) Biochemical determinants of changes in plasma volume after decongestion therapy for worsening heart failure. *J Card Fail* 25: 213-217.
8. Kataoka H (2019) Rationale of the “chloride theory” as an explanation for neurohormonal activity in heart failure pathophysiology: Literature review. *J Clin Exp Cardiol* 10: 634.
9. Kataoka H (2015) Clinical significance of bilateral leg edema and added value of monitoring weight gain during follow-up of patients with established heart failure. *ESC Heart Fail* 2: 106-115.
10. Kataoka H, Takada S (2000) The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure. *J Am Coll Cardiol* 35: 1638-1646.
11. Kataoka H (2007) Utility of thoracic sonography for follow-up examination of chronic heart failure patients with previous decompensation. *Clin Cardiol* 30: 336-341.
12. Kataoka H (2009) A new monitoring method for the estimation of body fluid status by digital weight scale incorporating bioelectrical impedance analyzer in definite heart failure patients. *J Card Fail* 15: 410-418.
13. Strauss MB, Davis RK, Rosenbaum JD, Rossmeisl EC (1951) “Water diuresis” produced during recumbency by the intravenous infusion of isotonic saline solution. *J Clin Invest* 30: 862-868.
14. Kalra PR, Anagnostopoulos C, Bolger AP, Coats AJS, Anker SD (2002) The regulation and measurement of plasma volume in heart failure. *J Am Coll Cardiol* 39: 1901-1908.
15. Espinel CH (1976) The FENa test. Use in the differential diagnosis of acute renal failure. *JAMA* 236: 579-581.
16. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Pool-Wilson P (1987) Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics. *Br Heart J* 57: 17-22.
17. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, et al. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the studies of Left Ventricular Dysfunction (SOLVD). *Circulation* 82: 1724-1729.
18. Johnson W, Omland T, Hall C, Lucas C, Myking OL, et al. (2002) Neurohormonal activation rapidly decrease after intravenous therapy with diuretics and vasodilators for class IV heart failure. *J Am Coll Cardiol* 39: 1623-1629.
19. Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, et al. (2015) Decongestive strategies and renin-angiotensin-aldosterone system activation in acute heart failure. *JACC Heart Fail* 3: 97-107.
20. Nijst P, Verbrugge FH, Martens P, Bertrand PB, Dupont M, et al. (2017) Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. *J Renin Angiotensin Aldosterone Syst* 18: 1-9.
21. Packer M (1985) Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure: The price we pay for interfering with evolution. *J Am Coll Cardiol* 6: 171-173.
22. Gupta S, Neyses L (2005) Diuretic usage in heart failure: A continuing conundrum in 2005. *Eur Heart J* 26: 644-649.
23. Verbrugge FH, Tang WHW, Mullens W (2015) Renin-angiotensin-aldosterone system activation during decongestion in acute heart failure: Friend or foe? *JACC Heart Fail* 3: 108-111.
24. Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, et al. (2016) Hypochloremia and diuretic resistance in heart failure: Mechanistic insights. *Circ Heart Fail* 9: e003180.
25. Grodin JL (2016) Pharmacologic approaches to electrolyte abnormalities in heart failure. *Curr Heart Fail Rep* 13: 181-189.
26. Martens P, Dupont M, Verbrugge FH, Damman K, Degryse N, et al. (2019) Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure. *JACC Heart Fail* 7: 404-414.
27. Pao AC, Chertow GM (2014) Urine electrolyte composition and diuretic therapy in heart failure: Back to the future? *Circ Heart Fail* 7: 697-698.
28. Kobayashi M, Stienen S, Ter Maaten JM, Dickstein K, Samani NJ, et al. (2020) Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. *ESC Heart Fail* 7: 953-963.
29. Kataoka H (2020) Proposal for new classification and practical use of diuretics according to their effects on the serum chloride concentration: Rationale based on the “chloride the-

-
- ory". *Cardiol Ther* 9: 227-244.
30. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bitner V, et al. (1994) Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry of Studies of Left Ventricular Dysfunction. *J Am Coll Cardiol* 23: 1410-1420.
 31. Volpe M, Magri P, Rao MA, Cangianiello S, DeNicola L, et al. (1997) Intrarenal determinants of sodium retention in mild heart failure: Effects of angiotensin-converting enzyme inhibition. *Hypertension* 30: 168-176.
 32. Damgaard M, Norsk P, Gustafsson F, Kanters JK, Christensen NJ, et al. (2006) Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. *Am J Physiol Regul Integr Comp Physiol* 290: R1294-R1301.
 33. Galve E, Mallol A, Catalan R, Palet J, Méndez S, et al. (2005) Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. *Eur J Heart Fail* 7: 892-898.

Copyright: ©2021 Hajime Kataoka,. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.